TECHNICAL NOTEEffect of forced diuresis during 18F-DCFPyL PET/CT in patients with prostate cancer activity in ureters, kidneys and bladder and occurrence of halo artefacts around kidneys and bladderWondergem, Maurits; van der Zant, Friso M.; Rafimanesh-Sadr, Ladan; Knol, Remco J.J.Author Information Department of Nuclear Medicine, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands Correspondence to Maurits Wondergem, MD, PhD, NWZ, Wilhelminalaan 12, 1815 JD, 0030, The Netherlands Tel: +31 725 483 480; fax: +31 725 483 484; e-mail: email@example.com Received October 22, 2018 Received in revised form February 5, 2019 Accepted February 14, 2019 Nuclear Medicine Communications: June 2019 - Volume 40 - Issue 6 - p 652-656 doi: 10.1097/MNM.0000000000001007 Buy Metrics Abstract Forced diuresis may improve readability of 2-(3-(1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentanedioic acid (18F-DCFPyL) PET/computed tomography (CT) by reducing focal ureteral activity. A total of 40 patients received furosemide simultaneously with 18F-DCFPyL (cohort 1) and 40 patients received furosemide 85 min after 18F-DCFPyL administration (cohort 2). The frequency of occurrence of activity depositions in ureters and halo artefacts near the kidneys and bladder was measured, as well as intensity of 18F-DCFPyL uptake in kidneys and bladder. At 120 min after injection of 18F-DCFPyL, a significantly lower number of 18F-DCFPyL depositions in ureters was found in cohort 2. Moreover, 18F-DCFPyL uptake in kidneys and bladder was significantly lower in this cohort; however, the occurrence of halo artefacts was similar in both groups. Administration of furosemide may improve interpretation of 18F-DCFPyL PET/CT as it results in less activity depositions in ureters. However, the effect depends on the timing of furosemide administration in relation to 18F-DCFPyL administration and PET/CT acquisition time. Acquisition of PET-images 120 min after 18F-DCFPyL administration benefits from late furosemide administration (85 min after injection). Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.